Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male, or a female who is not of child-bearing potential or who is non-pregnant, non-lactating, and is using a medically accepted method of contraception.~* Each participant must be willing and able to provide written informed consent.~* Each participant must have an identified external contact person or an identified responsible person.~* Current diagnosis of Bipolar 1 Disorder, and a current manic (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision \[DSM-IV-TR\^TM\] code 296.4x) or mixed (DSM-IV code 296.6x) episode as determined by a structured clinical interview (Mini International Neuropsychiatric Interview \[MINI\]) at Screening.~* Each participant must be confirmed to be experiencing an acute manic or mixed bipolar 1 episode.~Exclusion criteria:~* Uncontrolled, unstable clinically significant medical condition.~* Clinically significant abnormal laboratory, vital sign, physical examination, or electrocardiogram findings at Screening.~* Current primary Axis I disorder other than bipolar 1 disorder.~* Meets the current DSM-IV-TR\^TM criteria for substance abuse or dependence (excluding nicotine).~* Imminent risk of self-harm or harm to others.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asenapine (Type: EXPERIMENTAL): All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).